Abstract
Cisplatin-based chemotherapy has become an accepted standard in the adjuvant treatment of non-small-cell lung cancer (NSCLC). We present a case of acute myelogenous leukemia with an 11q23/MLL rearrangement diagnosed 1 year after the completion of 4 cycles of cisplatin and vinorelbine for resected NSCLC. To our knowledge, this is the first case of therapy-related acute myelogenous leukemia (t-AML) associated with this chemotherapy combination. The literature on t-AML with the 11q23/MLL rearrangement is reviewed.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Chromosomes, Human, Pair 11
-
Cisplatin / administration & dosage
-
Follow-Up Studies
-
Histone-Lysine N-Methyltransferase
-
Humans
-
Leukemia, Myeloid, Acute / chemically induced*
-
Leukemia, Myeloid, Acute / genetics
-
Lung Neoplasms / drug therapy
-
Male
-
Myeloid-Lymphoid Leukemia Protein / genetics
-
Translocation, Genetic / drug effects*
-
Vinblastine / administration & dosage
-
Vinblastine / analogs & derivatives
-
Vinorelbine
Substances
-
KMT2A protein, human
-
Myeloid-Lymphoid Leukemia Protein
-
Vinblastine
-
Histone-Lysine N-Methyltransferase
-
Cisplatin
-
Vinorelbine